How Antimicrobial Resistance and Emerging Infections Will Reshape Global Demographics Before 2050

An Evidence-Based Research Brief

Prepared for Policy Makers, Investors & Healthcare Leaders

Dr. Kadiyali Srivatsa

Executive Summary

The UN’s medium-fertility population projections forecast 9.7 billion people by 2050. These models account for declining birth rates but critically underestimate the impact of rising death rates driven by antimicrobial resistance (AMR) and emerging infectious diseases — particularly in the very regions expected to drive the most population growth: South Asia, Sub-Saharan Africa, and Southeast Asia.

The population infographic from Our World in Data projects Asia reaching 5.3 billion and Africa reaching 2.5 billion by 2050. These projections are based on the UN’s medium-fertility scenario, which models birth rate trends but assumes mortality improvements will continue on a linear trajectory. This document presents peer-reviewed evidence that this assumption is dangerously flawed.

The core thesis: The same antibiotic revolution that fuelled the 20th century’s population explosion is now reversing. Antimicrobial resistance, compounded by emerging infections, is driving a rising death rate that population models do not capture adequately. The regions projected for maximum growth — South Asia, Africa, and Southeast Asia — are precisely where AMR mortality will be most devastating.

1. The Antibiotic Dividend: How Antibiotics Built the Population Boom

To understand where we are going, we must understand what brought us here. The 20th century’s population explosion was not primarily a story of rising birth rates — it was a story of falling death rates, driven largely by the discovery and mass deployment of antibiotics.

The Numbers That Changed Everything

• Before antibiotics (pre-1940): Average life expectancy at birth was 47 years, even in industrialised nations. Infectious diseases — smallpox, cholera, pneumonia, tuberculosis, typhoid, and diphtheria — were the leading causes of death across all age groups.
• After antibiotics (post-1950s): Antibiotics extended the average human lifespan by 23 years. In the US, life expectancy rose from 47 years in 1900 to nearly 79 years by 2000. Infectious diseases fell from the #1 to #8 cause of death.
• The population effect: Global population doubled from 2.5 billion (1950) to 5 billion (1987) — a 37-year doubling. In 1900, the world had 1.6 billion people. By 2000, it had 6.1 billion. This fourfold increase was driven primarily by declining mortality from infections.

Key insight: Antibiotics didn’t just save individual lives — they were the single largest contributor to the demographic transition that produced the modern world’s population boom. If antibiotics drove population UP, their failure will drive population DOWN.

2. The Reversal: AMR Is Already Killing at Scale

Antimicrobial resistance is not a future threat. It is a present-day pandemic that is already killing more people than HIV/AIDS and malaria combined.

The Landmark GRAM Project Data (Lancet, September 2024)

The most comprehensive global analysis of AMR mortality, covering 204 countries and territories from 1990 to 2021, with forecasts to 2050, reveals the following:

Metric

Current (2021)

Projected (2050)

Deaths directly caused by AMR (per year)

1.14 million

1.91 million (+67.5%)

Deaths where AMR is a contributing factor (per year)

4.71 million

8.22 million (+74.5%)

Cumulative direct AMR deaths (2025–2050)

—

39 million

Cumulative AMR-associated deaths (2025–2050)

—

169 million

AMR deaths since 1990 (cumulative)

36+ million

—

For context: COVID-19 killed approximately 7 million people officially (with excess deaths estimated at 15–25 million) over roughly 3 years. AMR is projected to kill 39 million directly and be associated with 169 million deaths over 25 years — a slow-motion catastrophe that dwarfs the pandemic.

The Age Shift: A Demographic Time Bomb

The GRAM data reveal a critical age-related shift. While AMR deaths among children under 5 have fallen by 50% since 1990, deaths among those aged 70 and older have increased by more than 80%. By 2050, the over-70 age group will account for 65.9% of all AMR-attributable deaths — a 146% increase from 2022. This is particularly devastating because the regions expecting the greatest population growth are also experiencing the fastest-ageing populations.

3. Where AMR Hits Hardest: The Regions Projected for Maximum Growth

The geographic overlap between UN population growth projections and AMR mortality hotspots is the crux of this argument.

Region

UN Population Projection 2050

AMR Deaths 2025–2050 (Direct)

AMR Risk Level

South Asia (India, Pakistan, Bangladesh)

2.4 billion+

11.8 million

HIGHEST globally

Sub-Saharan Africa

2.1 billion+

6.63 million

VERY HIGH (highest death rate per capita)

Southeast Asia, East Asia & Oceania

2.8 billion+

8.96 million

VERY HIGH

Europe

704 million (declining)

Moderate

Moderate (better stewardship)

The three regions projected to contribute 85% of global population growth by 2050 are the same three regions that will bear over 70% of all AMR deaths. This is not a coincidence — it is a structural vulnerability.

India: The Epicentre of the Crisis

India, projected by the UN to be the world’s most populous country with 1.67 billion people by 2050, is simultaneously the global epicentre of the superbug crisis:

• 83% of Indian hospital patients are already carrying multidrug-resistant organisms (MDROs) — the highest rate globally (vs. 31.5% Italy, 20.1% US, 10.8% Netherlands). Published in The Lancet eClinicalMedicine, November 2025.
• Nearly 300,000 people in India died from AMR-related infections in 2019 alone. India bears the world’s highest burden of antibiotic-resistant tuberculosis.
• 58,000 Indian newborns die each year from drug-resistant infections. Approximately 33% of sepsis mortality in India is linked to AMR.
• Over 70% of patients harbour ESBL-producing bacteria (which render common antibiotics useless), and 23.5% carry carbapenem-resistant bacteria — resistant even to last-resort antibiotics.
• Antibiotics are routinely sold over the counter without prescriptions, self-medication is endemic, antibiotic residues from pharmaceutical manufacturing and animal husbandry leach into waterways, and antibiotic consumption increased 46% globally between 2000–2018. It’s 11 hours

India has been described by researchers as the “capital of antibiotic resistance”. Without intervention, the conditions that make India a population growth leader also make it the most vulnerable to AMR-driven mortality reversal.

4. The Compounding Threats: AMR Does Not Act Alone

AMR is not an isolated threat. It compounds with and accelerates a cascade of emerging infectious diseases that population models largely ignore.

Active and Emerging Infectious Threats (2024–2026)

Threat

Current Status

Regions at Risk

AMR Interaction

H5N1 Avian Influenza

81 confirmed human cases in 2024 (highest since 2015); spreading in US dairy herds; single mutation could enable human-to-human transmission

Global — Asia, Americas, Africa

Secondary bacterial infections from flu require antibiotics; AMR makes these fatal

Drug-Resistant Tuberculosis

TB was the deadliest infectious disease in 2024, killing 1.25 million people; MDR-TB rising sharply

South Asia, Sub-Saharan Africa

Direct AMR threat — TB is becoming untreatable

Cholera

1 billion people at risk; resurgent globally; limited vaccine supply

Africa, South Asia

V. cholerae developing drug resistance; treatment failures rising

Measles Resurgence

492,000 cases in 2025; countries with large outbreaks tripled since 2021; 95,000 deaths in 2024

Africa, South Asia, SE Asia

Measles suppresses immunity → secondary bacterial infections → untreatable with AMR

Mpox (Clade I)

Escalating in Africa; DRC, Uganda, Sierra Leone seeing thousands of cases

Africa, then global

Secondary infections in skin lesions; AMR complicates treatment

Candida auris (Fungal)

Accelerating globally; often pan-resistant; spreading in hospitals

Global (concentrated in LMICs)

Part of the broader AMR crisis — antifungal resistance is rising in parallel

The critical point: each of these threats is amplified by AMR. A flu pandemic becomes more deadly when secondary bacterial pneumonia cannot be treated. Measles kills more children when post-measles infections are drug-resistant. Surgery, cancer care, childbirth, and routine injuries all become potentially lethal when antibiotics fail. These cascading effects are not factored into population projections.

5. Why the UN Population Models Are Structurally Flawed

The UN’s medium-fertility projection (the basis for the infographic you shared) makes two critical assumptions that AMR renders invalid:

Assumption 1: Mortality improvements will continue linearly

The UN models assume that global life expectancy will continue to rise or plateau, following the trajectory set during the antibiotic era. They do not model scenarios in which life expectancy declines significantly due to a resurgence of infectious disease. However, the GRAM data show that AMR mortality is already rising—up 8% between 1990 and 2021—with a projected 67.5% acceleration by 2050. If life expectancy in South Asia and Africa were to reverse by 5–10 years (a conservative estimate if antibiotics fail for common infections), the population projections would be fundamentally different.

Consider the precedent: during the HIV/AIDS epidemic, life expectancy in several Sub-Saharan African countries dropped by 15–20 years. The UN had to repeatedly revise population projections downward for the region. AMR has the potential to create a similar — or worse — mortality shock, because it affects all infections, not just one virus.

Assumption 2: Healthcare capacity will scale with population

The projections implicitly assume that healthcare infrastructure will keep pace with population growth, maintaining or improving survival rates for infections, childbirth, surgery, and chronic disease management. But AMR undermines the very foundation of modern healthcare:

• Without effective antibiotics, routine surgeries (C-sections, joint replacements, appendectomies) carry an unacceptable risk of infection.
• Cancer chemotherapy becomes far more dangerous, as immunosuppressed patients cannot fight drug-resistant infections.
• Neonatal sepsis, already killing 58,000 Indian newborns annually from AMR, will worsen as resistance spreads.
• The economic burden of AMR — estimated to contribute $1–3.4 trillion in annual GDP loss by 2030 and push 24 million more people into extreme poverty — will degrade healthcare capacity precisely when it is most needed.

6. The Reversal Arithmetic: What the Numbers Actually Show

Here is the mathematical logic that population models are missing:

The Antibiotic Era Equation (1940s–2020s)

The Post-Antibiotic Era Equation (2025–2050+)

Antibiotics extended human lifespan by ~23 years

AMR is projected to cause 8.22 million deaths/year by 2050 (associated)

Child mortality from infections dropped >50%

Emerging infections (H5N1, cholera, MDR-TB) compound the AMR toll

Life expectancy rose from 47 to 79 years in developed nations

Without effective antibiotics, life expectancy could revert to 50–60 years in LMICs (estimates based on pre-antibiotic baseline + sanitation/WASH gains)

Population quadrupled from 1.6B to 6.1B (1900–2000)

169 million cumulative AMR-associated deaths (2025–2050) will create demographic drag, concentrated in high-growth regions

Infectious diseases fell from #1 to #8 cause of death

AMR already kills more than HIV/AIDS and malaria combined; by 2050, on par with cancer at 10 million deaths/year

Bottom line: The UN projects the world reaching 9.7 billion by 2050. But this projection was built in an era when antibiotics worked. If the antibiotic shield fails — and it is already failing — the death rate correction, especially in South Asia and Africa, could reduce the projected population by hundreds of millions. The question is not IF this correction will happen, but HOW SEVERE it will be.

7. Dr. Maya AI: The Solution the World Needs Before the Crisis Peaks

This is precisely why Dr. Maya AI exists. The GRAM Project’s own data shows that improved infection care and better access to appropriate antibiotics could avert 92 million deaths between 2025 and 2050. The greatest benefits would be in South Asia (31.7 million deaths averted), Sub-Saharan Africa (25.2 million), and Southeast Asia (18.7 million).

Dr. Maya’s colour-coded triage system — developed from Dr. Srivatsa’s Paediatric Assessment Triangle methodology and 50 years of clinical experience — is designed to achieve exactly this:

• Blue (Infection Protocol): Identifies infections early before they require antibiotics, promoting prevention over prescription.
• Red (Emergency): Routes genuine emergencies to hospital care, reducing delays that worsen outcomes.
• Green (Moderate): Guides appropriate self-care, reducing unnecessary antibiotic consumption that drives resistance.
• Yellow (Mild): Empowers individuals to trust their body’s natural recovery for mild conditions, avoiding unnecessary medical intervention.

Deployed through PREMA health kiosks, multilingual apps, and AI-driven triage across India’s 700,000 villages and urban slums, Dr. Maya can be the frontline defence that the GRAM researchers say is needed: prevention, early identification, and rational antibiotic use at population scale.

8. Conclusion: It’s Not Just Falling Birth Rates — It’s Rising Death Rates

The global conversation about population focuses almost exclusively on declining fertility. But the data presented in this brief reveals an equally important — and largely ignored — variable: rising mortality from drug-resistant infections.

The evidence is unambiguous:

• Antibiotics added 23 years to human lifespan and were the primary engine of 20th-century population growth.
• AMR is reversing this gain. 39 million direct deaths and 169 million associated deaths projected by 2050.
• The hardest-hit regions are those expected to grow the most. South Asia (11.8M direct AMR deaths), Africa (6.63M), Southeast Asia (8.96M).
• Emerging infections compound the crisis. H5N1, MDR-TB, cholera, measles resurgence, and fungal superbugs all interact with AMR to amplify death rates.
• UN population models do not account for this. They assume continued mortality improvement. The data shows the opposite trajectory.

India, with 83% of hospital patients carrying superbugs, 300,000 annual AMR deaths, 58,000 newborn deaths from drug-resistant infections, and the world’s highest burden of drug-resistant TB, is not on a trajectory to reach 1.67 billion by 2050 without a massive intervention. That intervention is Dr. Maya AI.

Key Sources

1. GRAM Project — “Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050.” The Lancet, September 2024.

2. Wellcome Trust — “New forecasts reveal 39 million deaths directly attributable to bacterial AMR between 2025–2050.” September 2024.

3. Nature India — “Why India is a stronghold for superbugs.” October 2024.

4. The Lancet eClinicalMedicine — Multicountry MDRO prevalence study (83% India rate). November 2025.

5. Hutchings, Truman & Wilkinson — “Antibiotics: past, present and future.” Current Opinion in Microbiology, 2019.

6. WOAH/UNEP — “Forecasting the Fallout from AMR: Human Health Impacts.” September 2024.

7. PMC — “The Treasure Called Antibiotics” — Life expectancy data pre/post antibiotic era.

8. Our World in Data / UN Medium-Fertility Scenario — Population projections by region (1900–2050F).

9. BlueDot — “The most notable infectious disease events of 2025.” January 2026.

10. Harvard DASH — “History Repeating? Avoiding a Return to the Pre-Antibiotic Age.”